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Abstract
Background: Apolipoprotein CIII (apoCIII) is considered to impair the anti-atherogenic effect of high density
lipoprotein (HDL) in coronary heart disease (CHD) patients, and apoCIII content in HDL (HDL-apoCIII) predicts
CHD more accurately. However, the relationship between HDL-apoCIII and CHD, and the effect of statin treatment on
HDL-apoCIII are still unclear. The aims of the study are to establish the association of HDL-apoCIII with CHD, and
investigate the effect of statin treatment on HDL-apoCIII in CHD patients.
Methods: We conducted a hospital-based observational study. Totally 80 non-CHD patients and 120 CHD patients
without statin treatment were previously enrolled in this study. All the CHD patients received statin treatment, and 63
of them were followed after 3 months of regular statin treatment. HDL sample of each patient was isolated by
density gradient ultracentrifugation from fasting venous plasma, and HDL-apoCIII of each patient was measured
by ELISA method.
Results: HDL-apoCIII was significantly higher in CHD patients than non-CHD patients (p < 0.05), and it was still an
independent predictor of CHD after adjusting for other factors. Total plasma apoCIII, especially HDL-apoCIII was
significantly elevated after statin treatment in CHD patients, whereas total cholesterol (TC), low density lipoprotein
cholesterol (LDL-c) and apolipoprotein B (apoB) were decreased significantly (p < 0.05). Compared with CHD patients
without diabetes mellitus (DM), the effect of statin treatment on apoCIII markers was minor in CHD patients with DM.
And HDL-apoCIII correlated with plasma TG significantly in non-CHD and CHD patients (p < 0.05), but the correlation in
CHD patients did not exist after statin treatment (p > 0.05).
Conclusions: HDL-apoCIII has a significant and positive association with CHD. Although conventional atherogenic lipid
markers have a significantly decrease in CHD patients after statin treatment, HDL-apoCIII has a further elevation at the
same time.
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Introduction
Coronary heart disease (CHD) is a chronic inflamma-
tory disease characterized with dyslipidemia [1–3].
Conventional lipid markers such as total cholesterol (TC),
triglyceride (TG), low-density lipoprotein cholesterol
(LDL-c) and high-density lipoprotein cholesterol (HDL-c)
are considered to associate with CHD positively or
inversely [4, 5]. However, not all the CHD patients have
dyslipidemia, and large clinical trials also fail to find
more heart benefits by further elevating HDL-c [6, 7].
Increasing evidences suggest that apolipoproteins in li-
poproteins or plasma may predict CHD better [5, 8],
and the biological function of HDL is associated with
its components much more [9].
As a major component of triglyceride-rich lipopro-
teins (TRL), apolipoprotein CIII (apoCIII) is considered
to participate in the process of CHD by disturbing
lipids lipolysis and promoting inflammation response
[10–12]. Studies found that apoCIII or apoCIII-containing
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lipoproteins had significant associations with CHD
[8, 13, 14]. Even the antiatherogenic function of HDL
was also impaired by apoCIII in CHD patients [15],
and elevated apoCIII content in HDL (HDL-apoCIII)
predicted the occurrence and progression of CHD in
prospective or retrospective studies [16–18]. However, the
relationship between HDL-apoCIII and CHD is still in-
conclusive because of the general usage of lipid-lowering
drugs in almost all studies above. Lipid-lowering drugs,
particularly statins were demonstrated to reduce the
progression of CHD and cardiovascular event signifi-
cantly by decreasing atherogenic lipids [19, 20]. To
date, it is still unclear if statin treatment has the same
effect on HDL-apoCIII in CHD patients. The objectives
of our study are to establish the association between
HDL-apoCIII and CHD, and investigate the effect of
statin treatment on HDL-apoCIII in CHD patients.
Method
Study design and population
The study was approved by the Ethics Committee of the
Fuwai Hospital (Approval No. 2012–382) and was regis-
tered at http://clinicaltrials.gov/ (Identification Number:
NCT 01543308). A written informed consent was pro-
vided to all study patients, and the study protocol con-
forms to the guidelines of Declaration of Helsinki.
We conducted a hospital-based observational study.
Patients without previously lipid-lowering treatment
were consecutively recruited from April 2012 to March
2013 in Ward IV of Fuwai Hospital. Total 200 patients, in-
cluding 80 non-CHD patients and 120 CHD patients,
were entered into the study. CHD was diagnosed ac-
cording to the angiographic results: stenosis ≥ 50 % in
at least one major coronary artery. All 120 CHD pa-
tients received statin treatment (atorvastatin calcium 20
or 40 mg/day, rosuvastatin calcium 10 mg/day, pravastatin
sodium 40 mg/day, or simvastatin 40 mg/day) regardless
of whether a stent was implanted or not. Sixty-three CHD
patients were followed after 3 months of regular statin
treatment (detailed information about the statin treatment
was listed in Additional files 3 and 4); 57 CHD patients re-
fused to return for blood drawing. Considered the effect
of Diabetes mellitus (DM) on lipids metabolism, the DM
history of each patient was recorded. DM was diagnosed
based on the National Cholesterol Education Program
Adults Treatment Panel III or personal DM history. A
total of 10 CHD patients with DM were followed in this
study, including 5 patients used acarbose (2 of them also
used glyburide or glipizide), 2 patients used insulin, and 3
patients used metformin, Chinese medicine and dietetic
treatment respectively. The exclusion criteria included pa-
tients with any kinds of tumors and infections, severe liver
or kidney diseases, uncontrolled hypertension, and severe
heart failure.
Plasma preparation
Venous blood was collected from each patient after
overnight fasting. Fresh plasma was obtained by centri-
fuging at 3000 r/min at 4 °C for 10 min immediately,
and then aliquoting the plasma for lipids measurement
or storage at −80 °C for HDL isolation and apoCIII
measurement.
HDL isolation
As described previously [21], a HDL (d = 1.063-1.240 g/ml)
sample of each patient was isolated from plasma by a
sequential ultracentrifugation method. Briefly, plasma
was adjusted to 1.240 g/ml by potassium bromide pow-
der according to the Radding-Steining formula. The ad-
justed plasma samples were laid on the bottom of a
centrifuge tube through KBr solution (d = 1.063 g/ml)
and was centrifuged by 80 Ti Rotor ultracentrifuge
(Beckman Coulter, USA) at the condition of 65000 r/min
at 10 °C for 5 h. Finally the HDL sample was collected,
desalted, freeze-dried, and resolved by deionized water for
measurement.
Lipids measurement
Lipid markers including TC, TG, HDL-c, LDL-c, apo-
lipoprotein AI (ApoAI), apolipoprotein B (ApoB) and
high sensitivity C-reactive protein (HsCRP) were mea-
sured by a biochemistry analyzer in the clinical laboratory
centre of Fuwai hospital, as described previously [21]. And
the plasma apoCIII concentrations and HDL-apoCIII were
measured by using an ELISA kit (Abcam, UK). The con-
centrations of HDL samples were quantified by using
BCA protein assay (Applygen Technologies Inc, China).
The effect of the differences of HDL sample concentra-
tions was considered, and all the ELISA results (ng/ml) of
HDL-apoCIII were adjusted by the concentrations (ug/ml)
of HDL samples, and the final HDL-apoCIII unit was re-
ported in ug/mgHDL.
Statistical analysis
All the data were expressed as mean ± standard devi-
ation (SD) or percent (%). Normality was checked be-
fore any analysis. The differences between groups were
analyzed by student t-test, paired t-test or Mann–Whitney
U test, or Wilcoxon rank test, as appropriate. A multivari-
ate logistic regression model was used to analyze the odds
ratios and 95 % confidence interval of lipid markers for
predicting CHD. The correlations between lipid markers
were analyzed by Pearson or Spearman correlation. The
statistical analysis was performed using SPSS version 17.0
(SPSS Inc., Chicago, Illinois). A p-value of <0.05 was con-
sidered to be statistically significant.
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Results
As shown Table 1, the elder males had a higher ratio of
CHD (p < 0.05), and the results consist to epidemiologic
features. Data stratified by sex were listed in Additional
file 1. Totally, compared with non-CHD patients, CHD
patients had significantly higher apoB and HsCRP, and
significantly lower HDL-c and apoAI than non-CHD pa-
tients (p < 0.05). There were no significant differences of
TC, TG and LDL-c between CHD and non-CHD groups
in this study (p > 0.05). However, there was no significant
difference of total plasma apoCIII between two groups
(p > 0.05), but HDL-apoCIII was significantly higher in
CHD patients than non-CHD patients (p < 0.01).
In order to identify the relationship between HDL-
apoCIII and CHD, we analyzed the associations be-
tween various lipid markers and CHD by multivariate
logistic regression analysis (Table 2). HDL-apoCIII was
still an independent predictor of CHD after adjusting for
other facors (p < 0.05). Besides, sex, age, HDL-c, apoB and
HsCRP were also significant predictors of CHD (p < 0.05).
According to the data, HDL-c has a negative, and HDL-
apoCIII has a positive association with CHD.
Sixty-three patients were followed in the study after
3 months of regular statin treatment, and the baseline
characteristics of them were consistent with the CHD
patients without follow-up data (Additional file 2, p > 0.05).
The plasma apoCIII, especially HDL-apoCIII, had a signifi-
cant elevation after statin treatment (p < 0.05), whereas
HDL-c and ApoAI were elevated, and TC, LDL-c and
apoB were decreased significantly (Table 3, p < 0.001).
Although a similar effect on lipids changes was found
in different statins, rosuvastatin showed a much stron-
ger effect on apoCIII markers than the others (Additional
file 3). We did not find an obvious dose-dependent effect
in different doses of atorvastain treatment (Additional file
4). As an inflammation factor, HsCRP (3.25 ± 3.38 mg/L vs
2.22 ± 2.49 mg/L) was also significantly decreased after
statin treatment (p < 0.01). In further analysis, the effect of
statin treatment on apoCIII markers were minor in CHD
patients with DM (p > 0.05), but the effect on plasma
apoCIII (11.14 ± 3.72 mg/L vs 12.95 ± 5.75 mg/L) and
HDL-apoCIII (25.19 ± 15.39 ug/mgHDL vs 30.84 ± 16.92
ug/mgHDL) were significant in CHD patients without
DM (Additional file 5, p < 0.05).
Table 1 Baseline characteristics of all the patients
Variables Non-CHD CHD p
(n = 80) (n = 120)
Male (%) 55.0 76.7 0.002
Age (years) 51.34 ± 8.35 55.52 ± 10.04 0.002
BMI (kg/m2) 26.19 ± 3.23 26.31 ± 3.50 0.697
Hypertension (%) 47.5 58.3 0.191
Diabetes (%) 11.3 19.2 0.247
TC (mmol/L) 4.71 ± 0.80 4.49 ± 0.94 0.088
TG (mmol/L) 1.62 ± 1.00 1.76 ± 0.84 0.079
HDL-c (mmol/L) 1.24 ± 0.36 1.02 ± 0.23 <0.001
LDL-c (mmol/L) 3.03 ± 0.78 2.88 ± 0.82 0.199
ApoAI (mmol/L) 1.48 ± 0.29 1.34 ± 0.24 0.001
ApoB (mmol/L) 1.07 ± 0.22 1.16 ± 0.31 0.020
Glucose(mmol/L) 5.64 ± 1.36 5.43 ± 1.56 0.327
HsCRP (mg/L) 1.75 ± 1.72 3.66 ± 3.58 <0.001
ApoCIII (mg/L) 12.68 ± 3.74 11.97 ± 4.94 0.275
HDL-apoCIII (ug/mgHDL) 21.00 ± 11.33 25.05 ± 12.98 0.024
Data are expressed as mean ± standard deviation or percent (%). CHD = coronary
heart disease; BMI = body mass index; TC = total cholesterol; TG = triglyceride;
HDL-c = high density lipoprotein cholesterol; LDL-c = low density lipoprotein
cholesterol; Apo = apolipoprotein; HsCRP = high sensitivity C-reactive protein;
HDL-apoCIII = apoCIII content in HDL
Table 2 Odds ratios (OR) and 95 % confidence intervals (CI) of
variables for predicting CHD
Variables OR 95 % CI p
Sex 3.02 1.20-7.59 0.019
Age 1.07 1.02-1.12 0.003
TC 1.03 0.33-3.22 0.961
TG 0.83 0.45-1.52 0.543
HDL-c 0.06 0.01-0.95 0.046
LDL-c 0.44 0.13-1.50 0.191
ApoAI 2.21 0.19-25.49 0.526
ApoB 9.48 1.01-88.75 0.049
ApoCIII 0.96 0.87-1.05 0.345
HDL-apoCIII 1.04 1.00-1.08 0.039
HsCRP 1.22 1.02-1.45 0.028
CHD= coronary heart disease; TC = total cholesterol; TG = triglyceride; HDL-c = high
density lipoprotein cholesterol; LDL-c = low density lipoprotein cholesterol;
Apo = apolipoprotein; HDL-apoCIII = apoCIII content in HDL
The following variables were entered in the multivariable regression model:
sex, age, BMI, TC, TG, HDL-c, LDL-c, lipoprotein a, apoAI, apoB, HsCRP, apoCIII,
HDL-apoCIII and concomitant disease hypertension and diabetes mellitus
Table 3 Effect of statin treatment on lipid variables in CHD
patients
Variables Statin treatment (n = 63) p
Pre-treatment Post-treatment
TC (mmol/L) 4.45 ± 0.98 3.85 ± 0.87 <0.001
TG (mmol/L) 1.68 ± 0.77 1.54 ± 0.76 0.138
HDL-c (mmol/L) 1.05 ± 0.25 1.21 ± 0.54 <0.001
LDL-c (mmol/L) 2.84 ± 0.84 2.19 ± 0.69 <0.001
ApoAI(mmol/L) 1.37 ± 0.24 1.49 ± 0.30 <0.001
ApoB (mmol/L) 1.16 ± 0.34 0.89 ± 0.29 <0.001
ApoCIII (mg/L) 11.30 ± 4.10 12.93 ± 5.71 0.045
HDL-apoCIII (ug/mgHDL) 24.26 ± 14.80 29.35 ± 16.46 0.003
CHD= coronary heart disease; TC = total cholesterol; TG = triglyceride; HDL-c = high
density lipoprotein cholesterol; LDL-c = low density lipoprotein; Apo = apolipopro-
tein; HDL-apoCIII = apoCIII content in HDL
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HDL-apoCIII had significant correlations with plasma
TG in non-CHD patients and CHD patients (Fig. 1a and
b, p < 0.05), but this correlation disappeared after statin
treatment (Fig. 1c, p > 0.05). However, plasma apoCIII
had a moderate correlation with TG in non-CHD, CHD
and statin treated CHD patients (r = 0.50, 0.59 and 0.58
respectively, p < 0.001); and HDL-apoCIII significantly
correlated to plasma apoCIII regardless of whether statin
drugs were used or not (r = 0.35, 0.31 and 0.35 respect-
ively, p < 0.05). In this study, we did not find significant
correlations between HDL-apoCIII or plasma apoCIII
and HDL-c or LDL-c (p > 0.05).
Discussion
In this study, we found that CHD patients had a sig-
nificant higher level of HDL-apoCIII than non-CHD
patients, and the association between HDL-apoCIII
and CHD was still significant after adjusting for other
variable factors. However, although conventional athero-
genic lipid and inflammation factors were significantly de-
creased, there was a further elevation of HDL-apoCIII in
CHD patients after statin treatment.
As an atherogenic factor, apoCIII exists in both HDL
and apoB-lipoproteins, and transfers between them
during the process of lipolysis [22–24]. Studies have
found that apoCIII may participate in the initiation and
progression of CHD through disturbing lipids metabol-
ism, promoting the adhesion of monocyte to endothe-
lial cell, and impairing the anti-apoptotic function of
HDL [10–12, 15]. There were also some clinical studies
found that HDL-apoCIII was significantly higher in
CHD patients than in non-CHD patients, which can be
used to predict the occurrence and progression of CHD,
as well as the recurrent cardiovascular event [8, 16, 17]. In
this study, in order to avoid potential effects of the con-
centration of HDL samples, we adjusted HDL-apoCIII
values by the concentration of HDL after measuring
apoCIII of HDL samples. And we also found a signifi-
cantly higher HDL-apoCIII in CHD patients than non-
CHD patients, and it still associated with CHD significantly
after adjusting for other variable factors. To some extent,
HDL-apoCIII was a better predictor of CHD than most
conventional lipid markers.
This is the first time we quantitatively measured a sig-
nificant elevation of HDL-apoCIII in CHD patients with
adjustment of the effect of HDL sample, and established
the association between HDL-apoCIII and CHD without
the effect of lipid-lowering drugs. We also found an in-
verse association of HDL-c and HDL-apoCIII with CHD,
a higher HDL-c predicts a lower risk of CHD, but a
higher HDL-apoCIII predicts a higher risk of CHD, this
finding was supported by the results of previous studies
[4, 5, 17, 18]. Studies have found that HDL lost its anti-
inflammatory and anti-atherogenic function in end-stage
renal diseases or acute phase response [25–27]. Perhaps
this condition also existed in CHD patients, and the ele-
vated HDL-apoCIII may be partly responsible for the
dysfunction of HDL in CHD patients, and the occur-
rence and progression of CHD. However, considered the
Fig. 1 Correlations between HDL-apoCIII and plasma triglyceride in
non-CHD patients (a) and CHD patients before (b) and after (c) statin
treatment. HDL-apoCIII = apoCIII content in HDL; TG = triglyceride
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inhibitory effect of apoCIII on lipolysis [24], the elevated
HDL-apoCIII may delay the further lipolysis of HDL in
CHD patients also. So, the biological function of HDL-
apoCIII in CHD patients may need further more study.
Lipid-lowering drugs, especially statins, are famous for
their cardiovascular protective role by decreasing athero-
genic, elevating antiatherogenic lipids and inhibiting in-
flammation response [19, 20, 28, 29]. An earlier study
indicated that lipid-lowering drugs (colestipol hydro-
chloride and niacin) significantly decreased conventional
lipids and delayed the progression of CHD, but they sig-
nificantly increased HDL-apoCIII [18]. Another study
also found although most CHD patients received statin
treatment, they still had higher apoCIII contents in
plasma and HDL, and the elevated apoCIII in HDL was
responsible for the impaired antiapoptotic effect of HDL
[15]. There was little studies reported that atorvastatin
can decrease plasma apoCIII [30], but this result was
still controversial [31]. In this study, we found a simi-
lar effect of statin treatment on atherogenic lipids
and inflammation factor as previous studies [19, 20,
29, 32], however, not as expected, plasma apoCIII, es-
pecially HDL-apoCIII has a significant elevation at
the same time. The result was partly consistent to
previous studies [15, 18], and all the results favored
the theory of apoCIII transfer, increased lipolysis of
TRL leads to increased transfer of apoCIII to HDL. How-
ever, no matter the elevation of HDL-apoCIII was natur-
ally or caused by statin treatment, an excessive elevated
HDL-apoCIII may impair, and even counteract the anti-
atherogenic effect of HDL and/or the benefits of statin
treatment. All the results might explain why further ele-
vating HDL-c could not increase heart benefits [6, 7], and
why there were still residual cardiovascular risks after sta-
tin treatment in CHD patients [33, 34].
We found a similar effect of statin treatment on lipid
markers in CHD patients with DM or not. Perhaps be-
cause of the small case number or the interaction of an-
tidiabetic drugs, we did not find a significant effect of
statin treatment on apoCIII markers in patients with
DM (n = 10). Our results were inconsistent with a previ-
ous study, which found a decrease of apoCIII in plasma
and HDL in DM patients after atorvastatin treatment
[35]. DM patients have higher risk of CHD than non-
diabetic patients [36, 37], although statin treatment re-
duces the risk of CHD by decreasing lipids, it also leads
to an increased risk of DM [38]. To date, there is little
information about the differences of effect of statins on
lipid markers among CHD patients, DM patients and
CHD patients with DM, maybe the effect are different
among them.
As reported previously [39], we also found a significant
correlation between HDL-apoCIII and TG. Perhaps be-
cause of the effect of dyslipidemia and statin drugs, the
correlation was weaker in CHD patients, and disap-
peared after statin treatment. However, the correlation
between apoCIII and TG or HDL-apoCIII was not af-
fected by statin drugs. As a part of the theory of apoCIII
transfer, we did not find a significant correlation be-
tween HDL-apoCIII and HDL-c or LDL-c.
Limitations
An important limitation of our study was that there
were no placebo controls because all the CHD patients
received statin treatmen. However, to some extent, the
self-control method and the consistency of the results to
previous studies favor the accuracy of the study. Al-
though ultracentrifuge is a golden standard to isolate
HDL, and we adjusted potential effect of HDL samples
on the apoCIII results as far as possible, there may be
some bias existing inevitably during the procedure.
Conclusions
Our study found that, HDL-apoCIII has a positive
and significant association with CHD. Although statin
treatment for CHD patients could decrease conventional
atherogenic lipid markers significantly, HDL-apoCIII also
has a significant elevation. The results may indicate a new
aspect for studying CHD and evaluating the effect of statin
treatment on the biological function of HDL in CHD
patients.
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